Retatrutide is designed to control appetite and blood sugar but also increase body’s energy expenditure, unlike other drugs
A new triple-action weekly jab for type 2 diabetes could significantly reduce blood sugar and body weight, according to phase 3 trial results.
Patients in the trial receiving weekly retatrutide injections for 40 weeks lost more than four times as much weight as those on placebo, while the average drop in long-term blood sugar (HbA1c) was more than twice that of the placebo.
The triple hormone drug mimics three gut hormones that help control your appetite, blood sugar and metabolism: GLP-1, GIP and glucagon. Unlike other diabetes medications such as Ozempic and Wegovy, which primarily target the GLP-1 pathway to suppress appetite, or Mounjaro, which contains GLP-1 plus GIP to control blood-sugar levels, retatrutide also engages the glucagon receptor, which helps increase energy expenditure.
Can we go back to using “injection”, rather than “jab”, please.
IIRC jab is British for injection like lorry for truck and The Guardian is a British news source.
I call it “mister sting-y”
Whoah. Non-emotionally-charged scientific terminology in my media outlet?? Not on my watch, pal.
It’s only emotionally charged in the states.
That’s a big ass air bubble. You’re gonna feel that shit.
If it’s sub-cut then they’re going to need to change needle first. 1mL should be okay.
That being said, I don’t think I’ve ever left a bubble in a non-IV injection. Does it feel weird?
Hey, glucagon tri-agonists finally reaching stage 3 trials, awesome. For those wanting the tldr, glucagon is kind of the opposite of insulin in your body, it is the hormone that signals your body to release sugar into the blood and use it. This does increase calorie expenditure ie. metabolism but it was largely dismissed as a weight loss option because it raises blood sugar which is fairly dangerous. However, GLP-1 drugs are so incredibly effective at controlling and levelling blood sugar as well as increasing insulin sensitivity that glucagon being added to existing dual agonist drugs to increase weight loss potential in people with dangerous amounts of body fat even after dual agonist use is being experimented with.
